1. Home
  2. AVDL vs DVAX Comparison

AVDL vs DVAX Comparison

Compare AVDL & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • DVAX
  • Stock Information
  • Founded
  • AVDL 2015
  • DVAX 1996
  • Country
  • AVDL Ireland
  • DVAX United States
  • Employees
  • AVDL N/A
  • DVAX N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • DVAX Biotechnology: Pharmaceutical Preparations
  • Sector
  • AVDL Health Care
  • DVAX Health Care
  • Exchange
  • AVDL Nasdaq
  • DVAX Nasdaq
  • Market Cap
  • AVDL 1.4B
  • DVAX 1.3B
  • IPO Year
  • AVDL 1996
  • DVAX 2004
  • Fundamental
  • Price
  • AVDL $15.66
  • DVAX $9.57
  • Analyst Decision
  • AVDL Strong Buy
  • DVAX Buy
  • Analyst Count
  • AVDL 8
  • DVAX 4
  • Target Price
  • AVDL $20.88
  • DVAX $26.50
  • AVG Volume (30 Days)
  • AVDL 1.5M
  • DVAX 2.0M
  • Earning Date
  • AVDL 11-11-2025
  • DVAX 11-06-2025
  • Dividend Yield
  • AVDL N/A
  • DVAX N/A
  • EPS Growth
  • AVDL N/A
  • DVAX N/A
  • EPS
  • AVDL N/A
  • DVAX N/A
  • Revenue
  • AVDL $221,075,000.00
  • DVAX $316,268,000.00
  • Revenue This Year
  • AVDL $64.56
  • DVAX $23.23
  • Revenue Next Year
  • AVDL $30.60
  • DVAX $16.57
  • P/E Ratio
  • AVDL N/A
  • DVAX N/A
  • Revenue Growth
  • AVDL 132.35
  • DVAX 26.66
  • 52 Week Low
  • AVDL $6.38
  • DVAX $9.20
  • 52 Week High
  • AVDL $16.66
  • DVAX $14.63
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 65.57
  • DVAX 39.47
  • Support Level
  • AVDL $14.78
  • DVAX $9.20
  • Resistance Level
  • AVDL $16.04
  • DVAX $9.94
  • Average True Range (ATR)
  • AVDL 0.57
  • DVAX 0.30
  • MACD
  • AVDL -0.11
  • DVAX -0.04
  • Stochastic Oscillator
  • AVDL 79.23
  • DVAX 31.90

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Share on Social Networks: